Home > Gastroenterology > ECCO 2018 > Novel treatment strategies > Comparative effectiveness of vedolizumab and ustekinumab in CD

Comparative effectiveness of vedolizumab and ustekinumab in CD

ECCO 2018

Vedolizumab and ustekinumab can both be considered for treatment in CD when conventional and anti-TNF medication fail.

As head-to-head trials are not available and methodological issues limit an indirect comparison based on the registration studies, Biemans et al. compared vedolizumab- and ustekinumab-treated CD patients in a real-life systematic observational cohort (Initiative on Crohn and Colitis case series) [17]. They reported that clinical remission and AEs were comparable between treatments after 24 weeks.

CD patients receiving either vedolizumab or ustekinumab in standard care were followed using predefined follow-up visits (at 0, 12, 24, 52, and 104 weeks). CD characteristics documented included clinical disease activity (HBI), inflammatory markers (CRP, FCP), hospital admissions, CD-related surgery and AEs. Clinical remission was defined as HBI <5. As the aim was to compare treatments, patients with a history of both studied treatment...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on